文献速递肝病

脂肪肝指数升高是HIV-HCV合并感染患者全因死亡的危险因素

Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study).
PubMed 文献 · Hepatology · 2020-01-24

在法国ANRS CO13 HEPAVIH队列983例HIV-HCV合并感染患者中,采用Cox比例风险模型分析发现,脂肪肝指数(FLI)≥60与全因死亡风险近乎翻倍独立相关(校正HR 1.91,95%CI 1.17-3.12,P=0.009)。该关联独立于HCV治愈、晚期纤维化、肝癌或肝移植史、肝硬化间接临床体征史及HIV CDC临床C期。

要点

  • FLI≥60与HIV-HCV合并感染者全因死亡风险近乎翻倍独立相关(校正HR 1.91)。
  • 该关联独立于HCV治愈、晚期纤维化、肝癌或肝移植史及HIV CDC C期。
  • 在直接抗病毒药物使HCV治愈率近100%的时代,非侵袭性脂肪变性标志物有助于识别高死亡风险合并感染者。

核心结论

  • FLI≥60是HIV-HCV合并感染者全因死亡的危险因素,独立于肝纤维化和HCV治愈。

研究设计与样本

  • 基于法国国家艾滋病与病毒性肝炎研究署CO13 HEPAVIH队列(983例患者,4432次访视)的Cox比例风险模型分析。

主要发现

  • 多因素调整后,FLI≥60者全因死亡风险近乎翻倍(校正HR 1.91,95%CI 1.17-3.12,P=0.009)。
  • HCV治愈与全因死亡风险降低相关(HR 0.21,95%CI 0.07-0.61,P=0.004)。
  • 晚期纤维化与全因死亡风险相关(HR 1.77,95%CI 1.00-3.14,P=0.05)。
  • 肝癌和/或肝移植史与全因死亡风险显著相关(HR 7.74,95%CI 3.82-15.69,P<10^-3)。
  • 肝硬化间接临床体征史(HR 2.80,95%CI 1.22-6.41,P=0.015)及HIV CDC临床C期(HR 2.88,95%CI 1.74-4.79,P<10^-3)与全因死亡风险相关。

关键数值与推荐

  • FLI≥60定义为脂肪肝指数升高。
  • 校正因素包括HCV治愈、晚期纤维化、肝癌和/或肝移植史、肝硬化间接临床体征史及HIV CDC临床C期。

临床怎么用

  • 在直接抗病毒药物使HCV治愈率近100%的时代,研究结果鼓励更系统地使用非侵袭性脂肪变性标志物,以帮助识别死亡风险较高的合并感染者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Human immunodeficiency virus (HIV)-hepatitis C virus (HCV)-coinfected patients are at high risk of metabolic complications and liver-related events, which are both associated with hepatic steatosis and its progressive form, nonalcoholic steatohepatitis, a known risk factor for mortality. The fatty liver index (FLI), a noninvasive steatosis biomarker, has recently drawn attention for its clinical prognostic value, although its capacity to predict mortality risk in HIV-HCV-coinfected patients has never been investigated. Using a Cox proportional hazards model for mortality from all causes, with data from the French National Agency for Research on Aids and Viral Hepatitis CO13 HEPAVIH cohort (983 patients, 4,432 visits), we tested whether elevated FLI (≥60) was associated with all-cause mortality. APPROACH AND RESULTS: After multiple adjustment, individuals with FLI ≥ 60 had almost double the risk of all-cause mortality (adjusted hazard ratio [95% confidence interval], 1.91 [1.17-3.12], P = 0.009), independently of the following factors: HCV cure (0.21 [0.07-0.61], P = 0.004), advanced fibrosis (1.77 [1.00-3.14], P = 0.05), history of hepatocellular carcinoma and/or liver transplantation (7.74 [3.82-15.69], P < 10-3 ), history of indirect clinical signs of cirrhosis (2.80 [1.22-6.41], P = 0.015), and HIV Centers for Disease Control and Prevention clinical stage C (2.88 [1.74-4.79], P < 10-3 ). CONCLUSIONS: An elevated FLI (≥60) is a risk factor for all-cause mortality in HIV-HCV-coinfected patients independently of liver fibrosis and HCV cure. In the present era of nearly 100% HCV cure rates thanks to direct-acting antivirals, these findings encourage the more systematic use of noninvasive steatosis biomarkers to help identify coinfected patients with higher mortality risk.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Barré T, Protopopescu C, Bani-Sadr F, et al. Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). Hepatology. 2020. PMID: 31466125. doi:10.1002/hep.30914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。